Bexarotene in Treating Patients With Metastatic Breast Cancer
A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer
Sponsor: Ligand Pharmaceuticals
Listed as NCT00003752, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Ligand Pharmaceuticals, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ligand Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United States, Boston, United States, Charlottesville, United States, Chicago, United States, Columbus, United States, East Lansing, United States, Honolulu, United States, Houston, United States, Jacksonville, United States, Little Rock, United States and 15 more location s